ChiCTR2000038978 版本V1.3 版本创建时间2021/01/10 00:45:07 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2000038978 

最近更新日期:

Date of Last Refreshed on:

2021-01-10 00:43:58 

注册时间:

Date of Registration:

2020-10-11 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

1064-nm Nd:YAG皮秒激光治疗萎缩性痤疮瘢痕的疗效和安全性评价临床研究

Public title:

Clinical study on efficacy and safety of 1064-nm Nd:YAG laser in treating atrophic acne scars

注册题目简写:

English Acronym:

研究课题的正式科学名称:

1064-nm Nd:YAG皮秒激光治疗萎缩性痤疮瘢痕的疗效和安全性评价临床研究

Scientific title:

Clinical study on efficacy and safety of 1064-nm Nd:YAG laser in treating atrophic acne scars

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

方富民 

研究负责人:

林彤 

Applicant:

Fang Fumin 

Study leader:

Lin Tong 

申请注册联系人电话:

Applicant telephone:

+86 18896578313

研究负责人电话:

Study leader's telephone:

+86 13951902258

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

+86 25-85414477

申请注册联系人电子邮件:

Applicant E-mail:

18896578313@163.com

研究负责人电子邮件:

Study leader's E-mail:

ddlin@hotmail.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

江苏省南京市玄武区蒋王庙街12号

研究负责人通讯地址:

江苏省南京市玄武区蒋王庙街12号

Applicant address:

12 Jiangwangmiao Street, Xuanwu District, Nanjing, Jiangsu, China

Study leader's address:

12 Jiangwangmiao Street, Xuanwu District, Nanjing, Jiangsu, China

申请注册联系人邮政编码:

Applicant postcode:

2140000

研究负责人邮政编码:

Study leader's postcode:

2140000

申请人所在单位:

中国医学科学院皮肤病医院(研究所)

Applicant's institution:

Institute of Dermatology, Chinese Academy of Medical Sciences

研究负责人所在单位:

中国医学科学院皮肤病医院(研究所)

Affiliation of the Leader:

Institute of Dermatology, Chinese Academy of Medical Sciences

是否获伦理委员会批准:

是/Yes

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

2020-KY-012

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

中国医学科学院北京协和医学院皮肤病医院伦理审查委员会

Name of the ethic committee:

Medical Ethics Committee of Hospital for Skin Diseases (Institute of Dermatology), Chinese Academy of Medical Sciences

伦理委员会批准日期:

Date of approved by ethic committee:

2020-09-15 00:00:00

伦理委员会联系人:

宦静

Contact Name of the ethic committee:

Huan Jing

伦理委员会联系地址:

江苏省南京市玄武区蒋王庙街12号

Contact Address of the ethic committee:

12 Jiangwangmiao Street, Xuanwu District, Nanjing, Jiangsu, China

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

中国医学科学院皮肤病医院(研究所)

Primary sponsor:

Hospital for Skin Diseases (Institute of Dermatology), Chinese Academy of Medical Sciences

研究实施负责(组长)单位地址:

江苏省南京市玄武区蒋王庙街12

Primary sponsor's address:

12 Jiangwangmiao Street, Xuanwu District, Nanjing, Jiangsu, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

江苏

市(区县):

南京

Country:

China

Province:

Jiangsu

City:

Nanjing

单位(医院):

中国医学科学院皮肤病医院

具体地址:

玄武区蒋王庙街12号

Institution
hospital:

Hospital for Skin Diseases (Institute of Dermatology), Chinese Academy of Medical Sciences

Address:

12 Jiangwangmiao Street, Xuanwu District

经费或物资来源:

研究生经费

Source(s) of funding:

Postgraduate Funds

Target disease:

Acne scars

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

比较不同遍数的1064-nm Nd:YAG皮秒点阵激光治疗萎缩性痤疮瘢痕的疗效及安全性。  

Objectives of Study:

To compare the efficacy and safety of 1064-nm Nd:YAG picosecond laser for treating atrophic acne scars.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

a) 年龄18至60周岁的健康男性和女性;
b) 诊断为萎缩性痤疮瘢痕且ECCA评分≥130的患者;
c) 能够并且愿意遵守所有访谈、治疗和评价的时间及要求;
d) 能够理解并提供书面的知情同意。

Inclusion criteria

1. Healthy men and women aged 18 to 60 years old;
2. Patients with atrophic acne scar and ECCA score >= 130;
3. Patients who can and are willing to comply with all the time and requirements of interview, treatment and evaluation;
4. Patients who can understand and provide written informed consent.

排除标准:

a) 有瘢痕疙瘩病史;
b) 妊娠、哺乳期妇女;
c) 已知对表面麻醉药物过敏;
d) 最近有暴晒史;
e) 既往有光敏史,过去6月内曾口服已知会增加光敏感度药物的患者;
f) 在初次治疗前的6个月内口服异维A酸或计划在治疗期间服用的患者;
g) 过去3月内面部曾接受过手术治疗包括:微创、填充、注射、整形手术或紫外光疗、强脉冲光、激光、射频治疗;
h) 既往有恶性肿瘤病史的患者;
i) 研究者认为受试者存在依从性差或有其它器质性疾病等问题而不适宜参加本临床研究的患者。

Exclusion criteria:

1. Patients with keloid history;
2. Pregnant and lactating women;
3. Patients who are known to be allergic to topical anesthetics;
4. Patients with a recent history of sun exposure;
5. Patients with a history of photosensitization, who have taken orally drugs known to increase photosensitivity in the past 6 months;
6. Patients who took isotretinoin orally within 6 months before the initial treatment or planned to take it during the treatment period;
7. Patients who have received surgical treatment in the past three months include: minimally invasive surgery, filling, injection, plastic surgery or ultraviolet light therapy, intense pulsed light, laser and radio frequency therapy;
8. Patients with previous history of malignant tumor;
9. The researchers think that the subjects have poor compliance or other organic diseases and are not suitable to participate in this clinical study.

研究实施时间:

Study execute time:

From 2020-10-13 00:00:00 To 2021-10-13 00:00:00  

征募观察对象时间:

Recruiting time:

From 2020-10-13 00:00:00 To 2021-10-13 00:00:00  

干预措施:

Interventions:

组别:

低遍数组

样本量:

30

Group:

low-time group

Sample size:

干预措施:

低遍数1064-nm Nd:YAG皮秒点阵激光

干预措施代码:

Intervention:

low-energy 1064-nm Nd:YAG laser

Intervention code:

组别:

高遍数组

样本量:

30

Group:

high-time group

Sample size:

干预措施:

高遍数1064-nm Nd:YAG皮秒点阵激光

干预措施代码:

Intervention:

high-energy 1064-nm Nd:YAG laser

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

江苏 

市(区县):

南京 

Country:

China 

Province:

Jiangsu 

City:

Nanjing 

单位(医院):

中国医学科学院皮肤病医院(研究所) 

单位级别:

三甲 

Institution
hospital:

Hospital for Skin Diseases (Institute of Dermatology), Chinese Academy of Medical Sciences

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

痤疮瘢痕权重评分

指标类型:

主要指标

Outcome:

échelle d’évaluation clinique des cicatrices d’acné, ECCA

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

调查者通用评分

指标类型:

次要指标

Outcome:

investigator global assessment, IGA

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

疼痛评分

指标类型:

次要指标

Outcome:

Pain Visual Analogue Scale

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

患者满意度评分

指标类型:

次要指标

Outcome:

Patient's satisfaction rate

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

不良反应

指标类型:

次要指标

Outcome:

Side effects

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

blood

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

标本中文名:

组织

组织:

Sample Name:

tissue

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

正在进行

Recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 60 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

随机数字表

Randomization Procedure (please state who generates the random number sequence and by what method):

Random number table

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

评价者单盲

Blinding:

Evaluator single-blind

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

我们将利用Resman临床试验公共管理平台实现数据共享

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

We will use the Resman clinical trial public management platform to share data

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

我们将利用CRF收集数据

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

We will use the CRF to collect data

数据与安全监察委员会:

Data and Safety Monitoring Committee:

有/Yes

注册人:

Name of Registration:

 2020-10-11 20:58:37